Arovella Therapeutics Limited (ALA.XA)
Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
As of 10:59AM AEST. Market open.
| Previous close | 0.1200 |
| Open | 0.1250 |
| Bid | 0.1200 x N/A |
| Ask | 0.1250 x N/A |
| Day's range | 0.1250 - 0.1250 |
| 52-week range | 0.0400 - 0.1850 |
| Volume | |
| Avg. volume | 1,373,578 |
| Market cap | N/A |
| Beta (5Y monthly) | -0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0170 |
| Earnings date | 28 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.While shareholders of Arovella Therapeutics (ASX:ALA) are in the black over 1 year, those who bought a week ago aren't so fortunate
It certainly might concern Arovella Therapeutics Limited ( ASX:ALA ) shareholders to see the share price down 31% in...
PR NewswireThe SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy
Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance with Arovella Therapeutics Ltd (ASX: ALA). This collaboration emphasizes the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-iNKT cell therapy.
© 2024 Yahoo. All rights reserved.